ZOGENIX INC (ZGNX) Stock Price & Overview
NASDAQ:ZGNX
Current stock price
The current stock price of ZGNX is 26.68 null. Today ZGNX is up by 1.6%. In the past month the price increased by 2.22%. In the past year, price increased by 28.64%.
ZGNX Key Statistics
- Market Cap
- 1.494B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.07
- Dividend Yield
- N/A
ZGNX Stock Performance
ZGNX Stock Chart
ZGNX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZGNX. When comparing the yearly performance of all stocks, ZGNX is one of the better performing stocks in the market, outperforming 98.84% of all stocks.
ZGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZGNX. ZGNX has a bad profitability rating. Also its financial health evaluation is rather negative.
ZGNX Earnings
ZGNX Forecast & Estimates
15 analysts have analysed ZGNX and the average price target is 37.3 null. This implies a price increase of 39.82% is expected in the next year compared to the current price of 26.68.
For the next year, analysts expect an EPS growth of 26.75% and a revenue growth 113.18% for ZGNX
ZGNX Groups
Sector & Classification
ZGNX Financial Highlights
Over the last trailing twelve months ZGNX reported a non-GAAP Earnings per Share(EPS) of -4.07. The EPS decreased by -5.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -278.4% | ||
| ROA | -48.54% | ||
| ROE | N/A | ||
| Debt/Equity | 0.88 |
ZGNX Ownership
ZGNX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZGNX
Company Profile
Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
Company Info
IPO: 2010-11-23
ZOGENIX INC
5959 Horton St Ste 500
Emeryville CALIFORNIA 94608 US
CEO: Stephen J. Farr
Employees: 218
Phone: 15105508300.0
ZOGENIX INC / ZGNX FAQ
What does ZOGENIX INC do?
Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
What is the current price of ZGNX stock?
The current stock price of ZGNX is 26.68 null. The price increased by 1.6% in the last trading session.
Does ZOGENIX INC pay dividends?
ZGNX does not pay a dividend.
How is the ChartMill rating for ZOGENIX INC?
ZGNX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ZGNX stock?
ZOGENIX INC (ZGNX) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy ZGNX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZGNX.
What is the next earnings date for ZGNX stock?
ZOGENIX INC (ZGNX) will report earnings on 2022-05-04.